Here are four notes:
1. The clinical trial compared the 24-month outcomes of Amedica’s porous silicon nitride product versus bone autograft for single-level cervical fusion.
2. The trial’s results showed the two had comparable outcomes.
3. The FDA will make its final decision regarding the product’s clearance in 60 days.
4. Once approved, Amedica will begin manufacturing and selling the CASCADE product.
More articles on devices:
Global spine surgery robots market to hit $2.77B by 2022 — 4 points
NuVasive stock reaches new 52-week high: 3 points
Asia Pacific spine surgery devices market to reach $2.2B by 2019 — 4 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
